登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06886139,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
The participants need to undergo pathological biopsy of tumor tissue.. Confirmed by histopathology with CD20-positive DLBCL, except for High-grade B-cell lymphoma with MYC and BCL2 rearrangements (HGBL-DH), and histologic transformed DLBCL according to the WHO 2022 revised classification standards.
入选标准第 2 条
Previously received anti-tumor treatment such as radiotherapy, biotherapy, immunotherapy at least 28 days before the first administration of this study; chemotherapy at least 21 days before the first administration of this study; hormone therapy at least 14 days before the first administration of this study.
入选标准第 6 条
Fully recovered from the acute toxic effects (except alopecia) to ≤ grade 1 (CTCAE 5.0) to prior anti-cancer therapy.
入选标准第 7 条
Prior treated with radiotherapy covering more than 30% of the bone marrow area.
入选标准第 17 条
Participants who received autologous stem cell transplantation and CAR-T within 3 months prior to first administration; Participants who have received allogeneic stem cell transplantation in the past.
入选标准第 24 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
入选标准第 9 条
Have measurable disease, including at least 1 nodal site measuring >1.5 cm or 1 extranodal site measuring >1.0 cm in longest dimension on computed tomography (CT).
入选标准第 5 条
For women of childbearing potential and men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception. For women of childbearing potential, a negative serum pregnancy test result within 7 days before the first administration.
入选标准第 11 条
Pregnancy and/or active Breast Feeding.
入选标准第 29 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06886139,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
≥ 18 years, gender is not limited. The participants need to undergo pathological biopsy of tumor tissue.. Confirmed by histopathology with CD20-positive DLBCL, except for High-grade B-cell lymphoma with MYC and BCL2 rearrangements (HGBL-DH), and histologic transformed DLBCL according to the WHO 2022 revised classification standards. Relapse or refractory after at least 2 lines of sufficient standard treatment regimens. Not considered to be eligible for Autologous Stem Cell Transplant (ASCT). Have measurable disease, including at least 1 nodal site measuring >1.5 cm or 1 extranodal site measuring >1.0 cm in longest dimension on computed tomography (CT). Previously received anti-tumor treatment such as radiotherapy, biotherapy, immunotherapy at least 28 days before the first administration of this study; chemotherapy at least 21 days before the first administration of this study; hormone therapy at least 14 days before the first administration of this study. Fully recovered from the acute toxic effects (except alopecia) to ≤ grade 1 (CTCAE 5.0) to prior anti-cancer therapy. Organ Function Requirements:Adequate hematologic, renal, and hepatic function. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Participants must have a life expectancy of ≥3 months. For women of childbearing potential and men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception. For women of childbearing potential, a negative serum pregnancy test result within 7 days before the first administration. All participants and/or their parents or legal guardians must sign a written informed consent form. A history of drug allergy to components of the test drug, xenoproteins, biological agents, etc., or severe infusion reaction after previous monoclonal antibody treatment. Serologic evidence of chronic hepatitis B virus (HBV) infection and unable or unwilling to receive standard prophylactic antiviral therapy or with detectable HBV viral load; Serologic evidence of hepatitis C virus (HCV) infection without completion of curative treatment or with detectable HCV viral load; Human immunodeficiency virus (HIV) seropositive. Tumor-infiltrating diseases of the central nervous system. Prior systemic treatment of lymphoma with MMAE-containing ADC drugs. Prior treated with radiotherapy covering more than 30% of the bone marrow area. ≥Grade 2 or greater baseline peripheral neuropathy. Investigator-assessed diabetes uncontrolled by drug therapy. Participants with other malignancies within the past 5 years. Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath, etc.). Active of autoimmune disease or immune deficiency. Accompanied significant cardiovascular disease. Participants who received autologous stem cell transplantation and CAR-T within 3 months prior to first administration; Participants who have received allogeneic stem cell transplantation in the past. Participants must not have an uncontrolled infection. Various vaccines were inoculated within 28 days prior to first administration. Participate in clinical trials of other drugs or medical devices within 28 days prior to first administration. Serious medical or psychiatric illness likely to interfere with participation in this clinical study. Pregnancy and/or active Breast Feeding. Investigators assessed as unsuitable to participate in this study for other reasons.排除标准:Exclusion Criteria:
引自 ClinicalTrials.gov, NCT06886139, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06886139,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。